Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-05-07
2011-11-29
Kolker, Daniel E (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016600
Reexamination Certificate
active
08067371
ABSTRACT:
This invention provides methods, compositions and articles of manufacture for inhibiting the onset of and treating inflammatory disorders such as rheumatoid arthritis. The instant invention is based on the blockade of RAGE G82S function.
REFERENCES:
patent: 5741486 (1998-04-01), Pathak et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 6007991 (1999-12-01), Sivaraman et al.
patent: 6071890 (2000-06-01), Scheule et al.
patent: 6271210 (2001-08-01), Sivaraman et al.
patent: 6465422 (2002-10-01), Schmidt et al.
patent: 6503887 (2003-01-01), During
patent: 6506559 (2003-01-01), Fire et al.
patent: 6555340 (2003-04-01), Schmidt et al.
patent: 6555651 (2003-04-01), Stern et al.
patent: 6563015 (2003-05-01), Stern et al.
patent: 6670136 (2003-12-01), Schmidt et al.
patent: 6677299 (2004-01-01), Stern et al.
patent: 6692966 (2004-02-01), Fallaux et al.
patent: 6697669 (2004-02-01), Dev et al.
patent: 6753150 (2004-06-01), Schmidt et al.
patent: 6790443 (2004-09-01), Stern et al.
patent: 6825164 (2004-11-01), Stern et al.
patent: 7026444 (2006-04-01), Schmidt et al.
patent: 7081241 (2006-07-01), Schmidt et al.
patent: 7101838 (2006-09-01), Stern et al.
patent: 7125675 (2006-10-01), Schmidt et al.
patent: 7258857 (2007-08-01), Stern et al.
patent: 7494972 (2009-02-01), Stern et al.
patent: 7700085 (2010-04-01), Stern
patent: 7732400 (2010-06-01), Stern et al.
patent: 2002/0122799 (2002-09-01), Stern et al.
patent: 2004/0142391 (2004-07-01), Schmidt
patent: 2005/0170382 (2005-08-01), Stern
patent: 2006/0078562 (2006-04-01), Mjalli
patent: 2007/0014791 (2007-01-01), Schmidt
patent: 2007/0167360 (2007-07-01), Yan et al.
patent: 2008/0019986 (2008-01-01), Stern
patent: 2008/0207499 (2008-08-01), Barile
patent: 2008/0214453 (2008-09-01), Stern
patent: 2008/0260717 (2008-10-01), Yan et al.
patent: 2009/0028882 (2009-01-01), Stern
patent: 2009/0060925 (2009-03-01), Mjalli
patent: 2009/0191210 (2009-07-01), Schmidt
patent: 2009/0220484 (2009-09-01), Schmidt
patent: 2009/0228997 (2009-09-01), Stern et al.
patent: WO 97/26913 (1997-07-01), None
patent: WO 99/54485 (1997-10-01), None
patent: WO 98/22138 (1998-05-01), None
patent: WO/99/07402 (1999-02-01), None
patent: WO 99/18987 (1999-04-01), None
patent: WO 00/20458 (2000-04-01), None
patent: WO/00/20621 (2000-04-01), None
patent: WO/01/12598 (2001-02-01), None
patent: WO/02/14519 (2002-02-01), None
patent: WO/02/30889 (2002-04-01), None
patent: WO/2004/100890 (2004-11-01), None
patent: WO/2005/023191 (2005-03-01), None
patent: WO/2005/042032 (2005-05-01), None
patent: WO/2005/427872 (2005-05-01), None
patent: WO/2006/017643 (2006-02-01), None
patent: WO/2006/099620 (2006-09-01), None
patent: WO/2008/153957 (2008-12-01), None
patent: WO/2009/058363 (2009-05-01), None
Hofmann, M.A., Drury, S., Fu, C., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides.Cell1999; 97: 889-901.
Chilosi, M., Mombello, A., Montagna, L., et al. Multimarker immunohistochemical staining of calgranulin, chloroacetate esterase, and S100 for simultaneous demonstration of inflammatory cells on paraffin sections.J. Histochem. Cytochem. 1990; 38: 1669-1675.
Youssef, P., Roth, J., Frosch, M.P., et al. Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane.J. Rheumatol. 1990; 26: 2523-2528.
Frosch, M., Strey, A., Vogl, T., et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis.Arthritis Rheum. 2000; 43: 628-637.
Zimmer, D.B., Cornwall, E.H., Landar, A., Song, W., The S100 protein family: history, function, and expression.Brain Research Bulletin1995; 37: 417-429.
Schafer, B.W., Heinzmann, C.W., The S100 family of EF-hand calcium-binding proteins: functions and pathology.TIBS1996; 21: 134-140.
Rammes, A., Roth, J., Goebeler, M., Klempt, M., Hartmann, M., Sorg, C., Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway.J. Biol. Chem. 1997; 272: 9496-9502.
Hudson, B.I., Stickland, M.H., Grant, P.J., Identification of polymorphisms in the Receptor for Advanced Glycation End Products (RAGE) gene.Diabetes1998; 47: 1155-1157.
Prevost, G., Fajardy, I., Fontaine, P., Danze, P.M., Besmond, C., Human RAGE Gly82Ser dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes.Europ. J. Immunogenet. 1999; 26: 343-348.
Neeper, M., Schmidt, A.M., Brett, J., et al. Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins.J. Biol. Chem. 1992; 267: 14998-15004.
Schmidt, A.M., Vianna, M., Gerlach, M., et al. Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface.J. Biol. Chem. 1992; 267: 14987-14997.
Kislinger, T., Fu, C., Huber, B., et al. Nε(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation endproducts that activate cell signalling pathways and modulate gene expression.J. Biol. Chem. 1999; 274: 31740-31749.
Yan, S.D., Chen, X., Fu, J., et al. RAGE and amyloid beta peptide neurotoxicity in Alzheimer's disease.Nature1996; 382: 685-691.
Hori, O., Brett, J., Slattery, T., et al. The receptor for advanced glycation endproducts (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and coexpression of RAGE and amphoterin in the developing nervous system.J. Biol. Chem. 1995; 270: 25752-25761.
Courtenay, J.S., Dallman, M.J., Dayan, A.D., Martin, A., Mosedale, B., Immunization against heterologous type II collagen induces arthritis in mice.Nature1980; 283: 666-668.
Trentham, D.E., Townes, A.S., Kang, A.H., Autoimmunity to type II collagen an experimental model of arthritis.J. Exp. Med. 1997; 146: 857-868.
Cathcart, E.S., Hayes, K.C., Gonnerman, W.A., Lazzari, A.A., Franzblau, C., Experimental arthritis in a nonhuman primate. I. Induction by bovine type II collagen.Lab. Invest. 1986; 54: 26-31.
Park, L., Raman, K.G., Lee, K.J., et al. Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE).Nature Medicine1998; 4: 1025-1031.
Quattrocchi, E., Walmsley, M., Browne, K., et al. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis.J. Immunol. 1999; 163: 1000-1009.
Neurath, M.F., Hildner, K., Becker, C., et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced artjrotos (CIA): a mechanism for methotrexate-mediated immunosuppression.Clin. Exp. Immunol. 1999; 115: 42-55.
Pugin, J., Widmer, M.C., Kosodo, S., Liang, C.M., Preas, H.L. II, Suffredini, A.F., Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators.Am. J. Respir. Cell Mol. Biol. 1999; 20: 458-464.
Lander, H.L., Tauras, J.M., Ogiste, J.S., Moss, R.A., Schmidt, A.M., Activation of the Receptor for Advanced Glycation Endproducts triggers a MAP Kinase pathway regulated by oxidant stress.J. Biol. Chem. 1997; 272: 17810-17814.
Taguchi, A., Blood, D.C., del Toro, G.A., et al. Blockade of amphoterin/RAGE signalling suppresses tumor growth and metastases.Nature 2000; 405: 354-360.
Pisetsky, D.S., Tumor necrosis factor blockers in rheumatoid arthritis.N. Engl. J. Med. 2000; 342: 810-811.
Boe, A., Baiocchi, M., Carbonatto, M., Papoian, R., Serlupi-Crescenzi, O., Interleukin-6 knock-out mice are resistant to antigen-induced experimental arthritis.Cytokine1999; 11: 1057-1064.
Robak, T., Gladalska, A., Stepien, H., Robak, E., Serum levels of interleukin-6 type cytokines and soluble interleukin- 6 receptor in patients with rheumatoid arthritis.Mediators Inflamm1998; 7: 347-353.
Keyszer, G., Lambiri, I., Nagel, R., et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloprotei
Schmidt Ann Marie
Stern David M.
Cooper & Dunham LLP
Emch Gregory S
Kolker Daniel E
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
RAGE G82S-related methods and compositions for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RAGE G82S-related methods and compositions for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RAGE G82S-related methods and compositions for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4273662